Amneal adds to US generics empire with four new launches

USA-based Amneal Pharmaceuticals (NYSE: AMRX) has announced that it has received Abbreviated New Drug Application (ANDA) approval from the US Food and Drug Administration (FDA) for four generics products.

This takes the total number of Amneal's generic launches this year alone to 16. The company is targeting between 20 and 30 in 2022.

The first generic is a vasopressin injection, which is a generic version of Par Pharmaceutical's antidiuretic hormone Vasostrict. According to IQVIA, the US brand and generic sales for vasopressin injection totalled approximately $624 million for the 12 months ended June 2022. It is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.